Abstracts tagged "Cardiovascular"

Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…
Abstract Number: 0820 • ACR Convergence 2025
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
Junjie Peng¹, Pierre Donnes¹, Thomas McDonnell¹, Laura Schanberg², Stacy Ardoin³, Laura Lewandowski⁴, George Robinson¹, Elizabeth C Jury¹ and Coziana Ciurtin¹, ¹University College London, London, United Kingdom, ²Duke University Medical Center, DURHAM, NC, ³Nationwide Children's Hospital, Columbus, OH, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…
Abstract Number: 0242 • ACR Convergence 2025
Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
Brittany Weber¹, Paul Cremer², Michael Garshick³, Sushil Allen Luis⁴, Ajit Raisinghani⁵, Vidhya Parameswaran⁶, Allison Curtis⁶, Allan Klein⁷ and John Paolini⁶, ¹Brigham and Women's Hospital, DEDHAM, MA, ²Cleveland Clinic, Shaker Heights, OH, ³NYU Langone Health, Tenafly, NJ, ⁴Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ⁵Division of Cardiology, Department of Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, ⁶Kiniksa Pharmaceuticals, LEXINGTON, MA, ⁷Cleveland Clinic, Cleveland, OH
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease (mediated by IL-1) that requires long-term treatment, and selection of therapy is guided by multiple factors.…
Abstract Number: 2681 • ACR Convergence 2025
Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
Tate Johnson¹, George Reed², Joel Kremer³, Dimitrios Pappas⁴, Punyasha Roul⁵, Grant Cannon⁶, Gail Kerr⁷, Andreas Reimold⁸, Katherine Liao⁹, Michael George¹⁰, Jon Giles¹¹, Christina Charles-Schoeman¹², Joshua Baker¹⁰, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Massachusetts Chan Medical School, Worcester, MA, ³The Corrona Research Foundation, Delray Beach, FL, ⁴CorEvitas, New York, NY, ⁵UNMC, Omaha, NE, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Cedars Sinai Medical Center, Los Angeles, CA, ¹²UCLA Medical Center, Santa Monica, CA
Background/Purpose: Total cholesterol (TC) and low-density lipoprotein (LDL) are critical measures of atherosclerotic cardiovascular disease (ASCVD) risk. However, the lipid paradox in RA, whereby systemic…
Abstract Number: 2363 • ACR Convergence 2025
Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE), yet the comparative safety of…
Abstract Number: 1892 • ACR Convergence 2025
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
siddharth Agrawal¹, Freya Shah¹, Ritu Tated², Radhe Shah³ and Mahir Modi⁴, ¹landmark medical center, cumberland, RI, ²New York Medical College, Vallaha, ³Beth Israel Deaconess Medical Center, Boston, ⁴GCS Medical College, hospital and Research Centre, Ahmedabad, India
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention…
Abstract Number: 1484 • ACR Convergence 2025
Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study
Mariana Vanoye Tamez¹, Freya Shah², Neel Patel³ and siddharth Agrawal², ¹New York Medical College / Landmark Medical Center, Providence, RI, ²landmark medical center, Cumberland, RI, ³University of Tennessee, Nashville
Background/Purpose: Patients with autoimmune connective tissue disease, such as Systemic Lupus Erythematosus (SLE), are at higher risk for developing aortic valve pathology. However, the impact…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Martin Michaud, Caroline Arlet, Jean Alain Bournazeau, François de Maupeou, Julie Gaston, Stephanie Mermet, Helene Coulier, Marie Oustalet, Christophe Raspaud, Cédric Maurice, Sophie Recipon, Claire Verplancken, Kim Paricaud and Leonardo Astudillo, Clinique Saint Exupery, TOULOUSE, France
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…
Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Claudia Iannone¹, Marco Di Battista², Maria Rosa Pellico³, ilaria Magi⁴, Antonina Minniti⁵, Giuseppe Armentaro⁴, Silvia Cavalli⁴, Manuel Sette⁴, Laura Giudice⁴, Cristina Bochicchio⁴, Alessandra Della Rossa⁶, Antonio Gaetano Tavoni⁷, Fabio Cacciapaglia⁸, Stefano Stano⁹, Martina Orlandi¹⁰, Dilia Giuggioli¹¹, Marta Mosca¹², Roberto Caporali¹³ and Nicoletta Del pAPA³, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ⁵ASST Gaetano Pini, milano, Milan, Italy, ⁶Rheumatology Unit, University of Pisa, Milan, Italy, ⁷Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Milan, Italy, ⁸Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁹⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ¹⁰Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ¹¹Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³University of Milan and ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…
Abstract Number: 2329 • ACR Convergence 2025
Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Sehneet Grewal, Rubab Rizwan, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, Poughkeepsie, NY
Background/Purpose: Psoriasis, a chronic inflammatory skin condition, is increasingly linked to systemic cardiovascular risks. Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with…
Abstract Number: 1883 • ACR Convergence 2025
Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.
Batko Bogdan¹, Mateusz Szeląg², Krzysztof Batko³, Magdalena Krajewska-Włodarczyk⁴, Zbigniew Żuber⁵, Marcin Stajszczyk⁶, Brygida Kwiatkowska⁷ and Tomasz Guzik⁸, ¹Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, ²Ministry of Health, Warsaw, Poland, ³Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, ⁴University of Warmia & Mazury, Olsztyn, Poland, ⁵Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, ⁶Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, ⁷Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, ⁸BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom
Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…
Abstract Number: 1483 • ACR Convergence 2025
Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
Fernanda M. Garcia-Garcia¹, Oscar Azael Garza-Flores², Esteban C. Garza-Gonzalez³, Rebeca L. Polina-Lugo⁴, Leslie Y. Lopez-Cantú¹, Dionicio A. Galarza-Delgado¹, Iris J. Colunga-Pedraza¹, Jesus Alberto Cardenas-de la Garza⁵, Jose R Azpiri-Lopez⁶ and Victor M Fraga-Enriquez⁷, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and accelerated atherosclerosis, leading to increased cardiovascular (CV) risk. While CV…
Abstract Number: 1008 • ACR Convergence 2025
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Hasan Satis¹, Umut Kalyoncu², Gizem Ayan³, Ali Aykut Fidanci⁴, Mustafa Mahir Ulgu⁴, Naim Ata⁴, Suayip Birinci⁴, Mehmet Koçak⁵ and Ahmet Gul⁶, ¹University of Health Sciences, Abdurrahman Yurtaslan Oncology Hospital, Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ³Ankara Research and Training Hospital, Ankara, Turkey, ⁴Ministry of Health, Ankara, Turkey, ⁵Medipol University, Istanbul, Turkey, ⁶Istanbul University, Istanbul, Turkey
Background/Purpose: While two trials with colchicine have demonstrated its efficacy in reducing the risk of cardiovascular events, a more recent study showed no significant impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].